Review



pdgf bb  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems pdgf bb
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Mouse%2FRat+PDGF-BB+Quantikine+ELISA+Kit/pmc12859453-603-9-10
    Average 94 stars, based on 60 article reviews
    pdgf bb - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming"

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2025.11.039

    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Figure Legend Snippet: Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

    Techniques Used: Staining, Immunofluorescence, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay

    SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).
    Figure Legend Snippet: SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

    Techniques Used: Isolation, In Vitro, Staining, Adoptive Transfer Assay, Transplantation Assay, Solvent, Control, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay, Marker

    Related Articles

    Recombinant:

    Article Title: Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
    Article Snippet: For transforming growth factor (TGF)-β induction, the HSCs were serum deprived for 4 h, subsequently treated with 10 μM SC-43 for 4 h, and followed by stimulation with 10 ng/mL recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) for 20 min. .. For PDGF-BB induction, the HSCs were serum deprived for 4 h, treated with 10 μM SC-43 for 4 h, followed by induction with 50 ng/mL recombinant human or rat PDGF-BB (R&D Systems) for 10 min on LX2 or HSC-T6 cells, respectively. .. For interleukin (IL)-6 stimulation, the HSCs were serum deprived for 4 h, treated with 10 μM SC-43 for 4 h, followed by induction with 100 ng/mL IL-6 (R&D Systems) for 30 min.

    Article Title: A Crosstalk between TGF-β/Smad3 and Wnt/β-Catenin Pathways Promotes Vascular Smooth Muscle Cell Proliferation
    Article Snippet: Dulbecco's modified Eagle's medium (DMEM) and other cell culture materials were purchased from Thermo Scientific (Rockford, IL). .. Recombinant human TGF-β1 and Wnts, as well as rat PDGF-bb were from R&D Systems (Minneapolis, MN). .. Niclosamide and SIS3 were from Sigma Aldrich (St. Louis, MO).

    Article Title: Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
    Article Snippet: For transforming growth factor (TGF)-β induction, the HSCs were serum deprived for 4 hours, subsequently treated with 10 μM 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea for 4 hours, and followed by stimulation with 10 ng/mL recombinant human TGF-β1 (R&D Systems, Minneapolis, Minn., USA) for 20 minutes. .. For platelet-derived growth factor (PDGF)-BB induction, LX2 cells or HSC-T6 cells were serum deprived for 4 hours, treated with 10 μM 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea for 4 hours, followed by induction with 100 ng/mL recombinant human or rat PDGF-BB (R&D Systems, USA) for 10 minutes. .. For interleukin (IL)-6 stimulation, the HSCs were serum deprived for 4 hours, treated with 10 μM 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea for 4 hours, followed by induction with 100 ng/mL IL-6 (R&D Systems, USA) for 30 minutes.

    Article Title: Antibodies against platelet-derived growth factor (PDGF)
    Article Snippet: The following day, the MSD anti-PDGF-Rβ phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. .. During blocking, anti-PDGF-BB supernatants, monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 M final concentration) and rat PDGF-BB (R&D Systems,cat#520-BB) (70 ng/ml/1.4E-9 M final concentration) for 30 minutes at 25° C. with shaking. ..

    Blocking Assay:

    Article Title: Antibodies against platelet-derived growth factor (PDGF)
    Article Snippet: The following day, the MSD anti-PDGF-Rβ phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. .. During blocking, anti-PDGF-BB supernatants, monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 M final concentration) and rat PDGF-BB (R&D Systems,cat#520-BB) (70 ng/ml/1.4E-9 M final concentration) for 30 minutes at 25° C. with shaking. ..

    Bioprocessing:

    Article Title: Antibodies against platelet-derived growth factor (PDGF)
    Article Snippet: The following day, the MSD anti-PDGF-Rβ phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. .. During blocking, anti-PDGF-BB supernatants, monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 M final concentration) and rat PDGF-BB (R&D Systems,cat#520-BB) (70 ng/ml/1.4E-9 M final concentration) for 30 minutes at 25° C. with shaking. ..

    Concentration Assay:

    Article Title: Antibodies against platelet-derived growth factor (PDGF)
    Article Snippet: The following day, the MSD anti-PDGF-Rβ phospho-assay plate (Mesoscale PDGF-Rβ-Tyr751 phospho-MSD kit cat# K150DVD-2) was blocked with MSD Blocker-A for 1 hour at 25° C. with shaking. .. During blocking, anti-PDGF-BB supernatants, monoclonal antibodies, benchmark compounds or DVD-Ig were serially diluted in growth media and pre-incubated with recombinant human PDGF-BB (CST, cat#8912BF) (20 ng/ml/7.94E-10 M final concentration) and rat PDGF-BB (R&D Systems,cat#520-BB) (70 ng/ml/1.4E-9 M final concentration) for 30 minutes at 25° C. with shaking. ..



    Similar Products

    94
    MedChemExpress pdgf bb
    SLC7A5 is upregulated during vascular remodeling. (A) Volcano plot of the GSE220512 dataset showing that Slc7a5 is significantly upregulated in neointimal tissue from mouse carotid arteries at Day 7 after wire injury compared with Day 0 controls. (B) Quantitative PCR analysis of SLC7A5 mRNA expression at indicated time points. (C) Representative Western blot and quantitative analysis showing SLC7A5 protein expression at 0, 7, and 14 days after vascular injury (n = 6). (D) Immunohistochemical staining of SLC7A5 in vascular tissues from sham, 7-day, and 14-day groups, showing increased expression in the medial layer during remodeling. bar = 50 μm. (E) Western blot and quantification of SLC7A5 expression in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs) (n = 3). (F) Immunofluorescence staining showing increased SLC7A5 expression in VSMCs <t>following</t> <t>PDGF-BB</t> stimulation compared with control. bar = 50 μm. Data are presented as mean ± SEM. Statistical significance is indicated as shown.
    Pdgf Bb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/PDGF-BB%2C+Rat/pmc13407181-35-13-15
    Average 94 stars, based on 1 article reviews
    pdgf bb - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems pdgf bb
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Mouse%2FRat+PDGF-BB+Quantikine+ELISA+Kit/pmc12859453-603-9-10
    Average 94 stars, based on 1 article reviews
    pdgf bb - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress a7r5 cells
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    A7r5 Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/PDGF-BB%2C+Rat/pm42010267-68-6-14
    Average 94 stars, based on 1 article reviews
    a7r5 cells - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology rat platelet derived growth factor pdgf
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Rat Platelet Derived Growth Factor Pdgf, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Rat+PDGF-BB+(Platelet+Derived+Growth+Factor+BB)+ELISA+Kit/pm41922477-62-16-14
    Average 94 stars, based on 1 article reviews
    rat platelet derived growth factor pdgf - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress platelet derived growth factor bb
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Platelet Derived Growth Factor Bb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/PDGF-AA%2C+Rat/pm41825614-74-24-28
    Average 94 stars, based on 1 article reviews
    platelet derived growth factor bb - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Cusabio vegf elisa kit
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Vegf Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Rat+platelet-derived+growth+factor-BB%2CPDGF-BB+ELISA+Kit/pm41679475-110-22-25
    Average 93 stars, based on 1 article reviews
    vegf elisa kit - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant rat pdgf bb
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) <t>and</t> <t>PDGF-BB</t> (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Recombinant Rat Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Recombinant+Rat+PDGF-BB+Protein/pm41520366-80-0-6
    Average 94 stars, based on 1 article reviews
    recombinant rat pdgf bb - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress platelet derived growth factor bb pdgf bb
    Single-cell RNA sequence analysis. A Lactate content in hPASMCs under hypoxic conditions. B Lactate content in hPASMCs <t>under</t> <t>PDGF-BB</t> stimulation conditions. C Hypoxia induces global and site-specific histone lactylation in hPASMCs. D Verification of mRNA expression of LCP1 in HPH. E Verification of mRNA expression of LCP1 in PAH F . Verification of protein expression of LCP1 in HPH. G Verification of protein expression of LCP1 in PAH. H Cell proliferation assessed by EdU assay. I Apoptpsis assessed by flow cytometry. * p < 0.05 vs normoxia; ** p < 0.01 vs normoxia; # p < 0.05 vs control; ## p < 0.01 vs control
    Platelet Derived Growth Factor Bb Pdgf Bb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/PDGF-AA%2C+Rat/pmc12866019-67-4-8
    Average 94 stars, based on 1 article reviews
    platelet derived growth factor bb pdgf bb - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Proteintech elisa assay kit
    Single-cell RNA sequence analysis. A Lactate content in hPASMCs under hypoxic conditions. B Lactate content in hPASMCs <t>under</t> <t>PDGF-BB</t> stimulation conditions. C Hypoxia induces global and site-specific histone lactylation in hPASMCs. D Verification of mRNA expression of LCP1 in HPH. E Verification of mRNA expression of LCP1 in PAH F . Verification of protein expression of LCP1 in HPH. G Verification of protein expression of LCP1 in PAH. H Cell proliferation assessed by EdU assay. I Apoptpsis assessed by flow cytometry. * p < 0.05 vs normoxia; ** p < 0.01 vs normoxia; # p < 0.05 vs control; ## p < 0.01 vs control
    Elisa Assay Kit, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+pdgf+bb/Mouse%2FRat+PDGF-BB+ELISA+Kit/pm41457305-131-6-12
    Average 93 stars, based on 1 article reviews
    elisa assay kit - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    SLC7A5 is upregulated during vascular remodeling. (A) Volcano plot of the GSE220512 dataset showing that Slc7a5 is significantly upregulated in neointimal tissue from mouse carotid arteries at Day 7 after wire injury compared with Day 0 controls. (B) Quantitative PCR analysis of SLC7A5 mRNA expression at indicated time points. (C) Representative Western blot and quantitative analysis showing SLC7A5 protein expression at 0, 7, and 14 days after vascular injury (n = 6). (D) Immunohistochemical staining of SLC7A5 in vascular tissues from sham, 7-day, and 14-day groups, showing increased expression in the medial layer during remodeling. bar = 50 μm. (E) Western blot and quantification of SLC7A5 expression in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs) (n = 3). (F) Immunofluorescence staining showing increased SLC7A5 expression in VSMCs following PDGF-BB stimulation compared with control. bar = 50 μm. Data are presented as mean ± SEM. Statistical significance is indicated as shown.

    Journal: Frontiers in Pharmacology

    Article Title: SLC7A5 promotes vascular remodeling in the rat carotid artery following balloon injury through PI3K/Akt signaling pathway

    doi: 10.3389/fphar.2026.1857850

    Figure Lengend Snippet: SLC7A5 is upregulated during vascular remodeling. (A) Volcano plot of the GSE220512 dataset showing that Slc7a5 is significantly upregulated in neointimal tissue from mouse carotid arteries at Day 7 after wire injury compared with Day 0 controls. (B) Quantitative PCR analysis of SLC7A5 mRNA expression at indicated time points. (C) Representative Western blot and quantitative analysis showing SLC7A5 protein expression at 0, 7, and 14 days after vascular injury (n = 6). (D) Immunohistochemical staining of SLC7A5 in vascular tissues from sham, 7-day, and 14-day groups, showing increased expression in the medial layer during remodeling. bar = 50 μm. (E) Western blot and quantification of SLC7A5 expression in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs) (n = 3). (F) Immunofluorescence staining showing increased SLC7A5 expression in VSMCs following PDGF-BB stimulation compared with control. bar = 50 μm. Data are presented as mean ± SEM. Statistical significance is indicated as shown.

    Article Snippet: JPH203 (KYT-0353) provided by Targetmol was dissolved in DMSO to prepare stock solution,and PDGF-BB from MCE (HY-P7278) was reconstituted in sterile normal saline according to the manufacturer’s instructions.

    Techniques: Real-time Polymerase Chain Reaction, Expressing, Western Blot, Immunohistochemical staining, Staining, Immunofluorescence, Control

    Knockdown of SLC7A5 inhibits PDGF-BB–induced VSMC proliferation, migration, and phenotypic switching. (A) Western blot analysis and quantification of PCNA expression in VSMCs under different treatments (n = 4). (B) Representative images of EdU staining and quantification of EdU-positive cells (n = 4) bar = 50 μm. (C) Western blot analysis and quantification of MMP2 expression (n = 4). (D) Representative images of wound healing assays at indicated time points and quantitative analysis of migration rate (n = 4) bar = 50 μm. (E) Western blot analysis and quantification of α-SMA expression (n = 4). (F) Representative immunofluorescence staining of α-SMA (green) and DAPI (blue), along with quantitative analysis of fluorescence intensity (n = 4) bar = 100 μm. PDGF-BB was used to induce VSMC activation. siSLC7A5 was used to silence SLC7A5 expression, and siNC served as a negative control. Data were presented as mean ± SEM from at four independent experiments. Statistical significance was determined using one-way ANOVA followed by appropriate post hoc tests.

    Journal: Frontiers in Pharmacology

    Article Title: SLC7A5 promotes vascular remodeling in the rat carotid artery following balloon injury through PI3K/Akt signaling pathway

    doi: 10.3389/fphar.2026.1857850

    Figure Lengend Snippet: Knockdown of SLC7A5 inhibits PDGF-BB–induced VSMC proliferation, migration, and phenotypic switching. (A) Western blot analysis and quantification of PCNA expression in VSMCs under different treatments (n = 4). (B) Representative images of EdU staining and quantification of EdU-positive cells (n = 4) bar = 50 μm. (C) Western blot analysis and quantification of MMP2 expression (n = 4). (D) Representative images of wound healing assays at indicated time points and quantitative analysis of migration rate (n = 4) bar = 50 μm. (E) Western blot analysis and quantification of α-SMA expression (n = 4). (F) Representative immunofluorescence staining of α-SMA (green) and DAPI (blue), along with quantitative analysis of fluorescence intensity (n = 4) bar = 100 μm. PDGF-BB was used to induce VSMC activation. siSLC7A5 was used to silence SLC7A5 expression, and siNC served as a negative control. Data were presented as mean ± SEM from at four independent experiments. Statistical significance was determined using one-way ANOVA followed by appropriate post hoc tests.

    Article Snippet: JPH203 (KYT-0353) provided by Targetmol was dissolved in DMSO to prepare stock solution,and PDGF-BB from MCE (HY-P7278) was reconstituted in sterile normal saline according to the manufacturer’s instructions.

    Techniques: Knockdown, Migration, Western Blot, Expressing, Staining, Immunofluorescence, Fluorescence, Activation Assay, Negative Control

    SLC7A5 knockdown attenuates the activation of the PI3K/Akt signaling pathway induced by PDGF-BB. (A–C) Western blot analysis of PI3K/Akt signaling pathway–related proteins, including phosphorylated PI3K (p-PI3K), total PI3K, phosphorylated Akt (p-Akt), and total Akt.

    Journal: Frontiers in Pharmacology

    Article Title: SLC7A5 promotes vascular remodeling in the rat carotid artery following balloon injury through PI3K/Akt signaling pathway

    doi: 10.3389/fphar.2026.1857850

    Figure Lengend Snippet: SLC7A5 knockdown attenuates the activation of the PI3K/Akt signaling pathway induced by PDGF-BB. (A–C) Western blot analysis of PI3K/Akt signaling pathway–related proteins, including phosphorylated PI3K (p-PI3K), total PI3K, phosphorylated Akt (p-Akt), and total Akt.

    Article Snippet: JPH203 (KYT-0353) provided by Targetmol was dissolved in DMSO to prepare stock solution,and PDGF-BB from MCE (HY-P7278) was reconstituted in sterile normal saline according to the manufacturer’s instructions.

    Techniques: Knockdown, Activation Assay, Western Blot

    Inhibition of SLC7A5 suppresses PDGF-BB–induced VSMC activation and PI3K/Akt signaling in vitro . (A) Western blot analysis and quantification of PCNA expression (n = 4). (B) Representative images of EdU staining and quantification of proliferating cells. bar = 100 μm. (C) Western blot analysis and quantification of MMP2 expression (n=4). (D) Representative images of wound healing assays at 0 h and 24 h, and quantitative analysis of migration rate. bar=100 μm. (E) Western blot analysis and quantification of α-SMA expression (n=4). (F) Representative immunofluorescence staining of α-SMA (green) and DAPI (blue). bar=100 μm. (G) Western blot analysis of PI3K/Akt signaling pathway–related proteins, including phosphorylated PI3K (p-PI3K), total PI3K, phosphorylated Akt (p-Akt), and total Akt (n=4). Data are presented as mean ± SEM from at four independent experiments. Statistical significance was determined by one-way ANOVAfollowed by appropriate post hoc tests. bar=100 μm.

    Journal: Frontiers in Pharmacology

    Article Title: SLC7A5 promotes vascular remodeling in the rat carotid artery following balloon injury through PI3K/Akt signaling pathway

    doi: 10.3389/fphar.2026.1857850

    Figure Lengend Snippet: Inhibition of SLC7A5 suppresses PDGF-BB–induced VSMC activation and PI3K/Akt signaling in vitro . (A) Western blot analysis and quantification of PCNA expression (n = 4). (B) Representative images of EdU staining and quantification of proliferating cells. bar = 100 μm. (C) Western blot analysis and quantification of MMP2 expression (n=4). (D) Representative images of wound healing assays at 0 h and 24 h, and quantitative analysis of migration rate. bar=100 μm. (E) Western blot analysis and quantification of α-SMA expression (n=4). (F) Representative immunofluorescence staining of α-SMA (green) and DAPI (blue). bar=100 μm. (G) Western blot analysis of PI3K/Akt signaling pathway–related proteins, including phosphorylated PI3K (p-PI3K), total PI3K, phosphorylated Akt (p-Akt), and total Akt (n=4). Data are presented as mean ± SEM from at four independent experiments. Statistical significance was determined by one-way ANOVAfollowed by appropriate post hoc tests. bar=100 μm.

    Article Snippet: JPH203 (KYT-0353) provided by Targetmol was dissolved in DMSO to prepare stock solution,and PDGF-BB from MCE (HY-P7278) was reconstituted in sterile normal saline according to the manufacturer’s instructions.

    Techniques: Inhibition, Activation Assay, In Vitro, Western Blot, Expressing, Staining, Migration, Immunofluorescence

    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

    Article Snippet: Levels of angiogenesis-associated factors, including VEGF (Neobioscience, EMC103.96) and PDGF-BB (R&D Systems, MBB00), were quantified in both bone marrow supernatants and serum using ELISA kits according to the manufacturer's instructions.

    Techniques: Staining, Immunofluorescence, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay

    SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

    Article Snippet: Levels of angiogenesis-associated factors, including VEGF (Neobioscience, EMC103.96) and PDGF-BB (R&D Systems, MBB00), were quantified in both bone marrow supernatants and serum using ELISA kits according to the manufacturer's instructions.

    Techniques: Isolation, In Vitro, Staining, Adoptive Transfer Assay, Transplantation Assay, Solvent, Control, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay, Marker

    Single-cell RNA sequence analysis. A Lactate content in hPASMCs under hypoxic conditions. B Lactate content in hPASMCs under PDGF-BB stimulation conditions. C Hypoxia induces global and site-specific histone lactylation in hPASMCs. D Verification of mRNA expression of LCP1 in HPH. E Verification of mRNA expression of LCP1 in PAH F . Verification of protein expression of LCP1 in HPH. G Verification of protein expression of LCP1 in PAH. H Cell proliferation assessed by EdU assay. I Apoptpsis assessed by flow cytometry. * p < 0.05 vs normoxia; ** p < 0.01 vs normoxia; # p < 0.05 vs control; ## p < 0.01 vs control

    Journal: Respiratory Research

    Article Title: Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration

    doi: 10.1186/s12931-025-03446-9

    Figure Lengend Snippet: Single-cell RNA sequence analysis. A Lactate content in hPASMCs under hypoxic conditions. B Lactate content in hPASMCs under PDGF-BB stimulation conditions. C Hypoxia induces global and site-specific histone lactylation in hPASMCs. D Verification of mRNA expression of LCP1 in HPH. E Verification of mRNA expression of LCP1 in PAH F . Verification of protein expression of LCP1 in HPH. G Verification of protein expression of LCP1 in PAH. H Cell proliferation assessed by EdU assay. I Apoptpsis assessed by flow cytometry. * p < 0.05 vs normoxia; ** p < 0.01 vs normoxia; # p < 0.05 vs control; ## p < 0.01 vs control

    Article Snippet: For drug-induced PAH modeling, Platelet-Derived Growth Factor-BB (PDGF-BB) (MCE, New Jersey, USA) was administered to hPASMCs at a concentration of 20 ng/mL.

    Techniques: Sequencing, Expressing, EdU Assay, Flow Cytometry, Control